SAB Biotherapeutics (NASDAQ:SABS) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of SAB Biotherapeutics (NASDAQ:SABS) from a sell rating to a hold rating in a report issued on Saturday morning.

Several other brokerages also recently weighed in on SABS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SAB Biotherapeutics in a research note on Monday, November 17th. Chardan Capital reaffirmed a “buy” rating and set a $12.00 price objective on shares of SAB Biotherapeutics in a research report on Monday, November 17th. Leerink Partners assumed coverage on SAB Biotherapeutics in a research note on Wednesday, September 17th. They issued an “outperform” rating and a $7.00 price objective on the stock. Finally, Leerink Partnrs raised SAB Biotherapeutics to a “strong-buy” rating in a research note on Wednesday, September 17th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, SAB Biotherapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.33.

SAB Biotherapeutics Price Performance

SABS stock opened at $3.95 on Friday. The business’s fifty day moving average price is $2.76 and its 200 day moving average price is $2.31. SAB Biotherapeutics has a 12-month low of $1.00 and a 12-month high of $6.60. The company has a current ratio of 10.49, a quick ratio of 0.87 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $188.06 million, a PE ratio of -1.28 and a beta of 0.60.

SAB Biotherapeutics (NASDAQ:SABS) last released its earnings results on Friday, November 14th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.38. On average, sell-side analysts anticipate that SAB Biotherapeutics will post -3.69 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in SABS. ADAR1 Capital Management LLC purchased a new stake in SAB Biotherapeutics during the third quarter worth approximately $30,000. Dimensional Fund Advisors LP acquired a new stake in SAB Biotherapeutics during the third quarter worth approximately $32,000. Virtu Financial LLC purchased a new stake in shares of SAB Biotherapeutics during the 3rd quarter worth approximately $40,000. HB Wealth Management LLC boosted its holdings in shares of SAB Biotherapeutics by 10.9% in the 1st quarter. HB Wealth Management LLC now owns 263,200 shares of the company’s stock valued at $358,000 after buying an additional 25,800 shares in the last quarter. Finally, Woodline Partners LP acquired a new position in shares of SAB Biotherapeutics in the 3rd quarter valued at $5,730,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.